Amicus Briefs

BIO submits amicus briefs on a variety of topics because of the strong interest and relevance to the biotechnology industry.

Featured Amicus Briefs
BIO Files Amicus Brief in Delaware Supreme Court…
BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …
BIO Files Amicus Briefs Supporting the Lawfulness…
On February 10, 2025, BIO filed an amicus brief in the U.S. District Court for the District of Columbia, supporting the lawfulness of plaintiff Eli Lilly's proposed 340B rebate model. The 340B Drug Pricing Program ("340B"), through which Medicaid…
BIO Files Amicus Brief on FDA Orange Book Listing…
BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit urging rehearing of a case involving whether certain Teva Pharmaceuticals patents had been properly listed in FDA’s Orange Book (Approved Drug Products with Therapeutic…
All Amicus Briefs
  • Show All
Search
Results
March 2, 2016
The questions presented in this case implicate two of the foundational legal conclusions that have allowed the PTAB, even in a relatively short time, to cut a remarkable swath through the ranks of issued patents with barely a…
February 16, 2016
BIO as Amicus Curiae supporting en banc reconsideration in Prolitec, Inc. v. ScentAir Technologies, Inc. (US Court of Appeals for the Federal Circuit)   STATEMENT OF INTEREST OF AMICUS CURIAE The Biotechnology Innovation Organization (&ldquo…
February 16, 2016
Brief of Amicus Curiae Biotechnology Innovation Organization in Support of Plaintiffs-Appellees in Amgen Inc. v. Apotex Inc. (U.S. Court of Appeals for the Federal Circuit) INTEREST OF AMICUS CURIAE   The Biotechnology Innovation Organization (…